Skip to Content
Merck
CN
All Photos(1)

Documents

SML3155

Sigma-Aldrich

Brincidofovir

≥98% (HPLC)

Synonym(s):

3-(Hexadecyloxy)propyl hydrogen ((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yloxy)methylphosphonate, CMX 001, CMX001, Hexadecyloxypropyl-cidofovir

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C27H52N3O7P
CAS Number:
Molecular Weight:
561.69
MDL number:
UNSPSC Code:
51111800
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Biochem/physiol Actions

Brincidofovir is an orally bioavailable prodrug of cidofovir with activity against pox viruses as well as CMV, HSV, and Varicella zoster.

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2 - Repr. 2 - Skin Sens. 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Erik De Clercq
Medicinal research reviews, 33(6), 1249-1277 (2013-03-16)
Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed-dose combinations (FDCs), the most recent example being Stribild(TM); (ii) for hepatitis C virus (HCV), the pleiade of direct-acting antivirals (DAAs)
R Anthony Vere Hodge et al.
Advances in pharmacology (San Diego, Calif.), 67, 1-38 (2013-07-28)
This review starts with a brief description of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), the clinical diseases they cause, and the continuing clinical need for antiviral chemotherapy. A historical overview describes the progress from the early
Julio J Alvarez-Cardona et al.
Future microbiology, 15, 389-400 (2020-03-14)
Brincidofovir (BCV) is a lipid conjugate of cidofovir with good oral bioavailability, enabling optimal intracellular levels of the active drug. Lower rates of nephrotoxicity and myelotoxicity make it a favorable alternative. Despite a greater safety profile among pediatric hematopoietic cell transplant

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service